A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
Eisai said on July 26 that the European Medicines Agency (EMA) has recommended against approving its Alzheimer’s treatment Leqembi (lecanemab) - a setback that came despite a series of green lights picked up in other markets. The EMA’s Committee for…
To read the full story
Related Article
- Austria, Germany Become First EU Markets to Launch Leqembi
August 26, 2025
- Eisai’s Alzheimer’s Drug Leqembi Now Approved in Europe
April 16, 2025
- EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
- Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
- EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
- Lecanemab Application Accepted for Review in Europe; FY2023 Approval Eyed
January 30, 2023
BUSINESS
- Japan Ethical Drug Sales Jump 9.7% in September: Crecon
November 11, 2025
- Kaken’s KP-001 Hits Goal in PIII Vascular Malformation Trial
November 11, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
- Keytruda Still Dominates Japan Drug Market in October: Encise
November 10, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…